Manufacturing, Bottlenecks, from DNA to product
Our world needs innovation in vaccine manufacturing
Making vaccines and therapeutic products for the world is a highly complex enterprise. The COVID-19 pandemic has shown a great need for science and technology to quickly develop effective and affordable solutions.
For protein-based therapeutics and prophylactic agents, from DNA to product, poor manufacturability is one of the major bottlenecks that prevents great ideas from making it to the clinic and market.
ExcellGene aims to bring people together to discuss these bottlenecks and challenges: top scientists, thought leaders, regulatory experts, investors and political representatives, covering industry and academia.
On August 30th 2022, meet us in Lausanne, Switzerland for a one-day (free of cost!) symposium of talks, discussion and networking.
Let us reflect, learn, push for innovation and remove barriers, and thus pave the way for modern and efficient approaches in developing vaccines and therapeutics on a global scale.
A different kind of scientific symposium
Conferences on bioprocessing for biological products often seem to miss the main reasons why manufacturability is a key factor that hinders progress to clinical trials.
Good ideas are not lacking, but getting things done is cumbersome. To explore and ensure effective discussion on the subject, this symposium will focus on:
- Manufacturing of protein-based antigen from clonally derived cell lines?
- Needs to show removal of theoretical virus load from CHO cells that never had an issue with virus loads in harvests of cell culture?
- Proof of clonality: an unnecessary exercise due to misunderstanding by regulatory examiners?
- Purity in antigen preparations for recombinant vaccines: how far must we go?
- Cell line stability studies: 3 month of wasted time?
- FiM studies with microgram-quantities of protein, do we need non-human primate studies first?